HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by BUTRER, J. F. Articles by SAHS, A. L. Search for Related Content PubMed PubMed Citation Articles by BUTRER, J. F. Articles by SAHS, A. L.

Amantadine in Parkinson's disease

A double-blind, placebo-controlled, crossover study with long-term follow-up

Department of Neurology, University of Iowa, College of Medicine, Iowa City, Iowa.

A double-blind, placebo-controlled, crossover study with long-term follow-up of amantadine in Parkinson's disease was performed on 26 patients. Other antiparkinsonian medications were discontinued in all but three patients. Amantadine resulted in a statistically significant 12 percent overall improvement over placebo. Twenty of 26 patients, without breaking the code, selected amantadine for long-term usage. Ten patients continued treatment for 10 to 12 months, and an overall statistically significant improvement was noted at 2 weeks and at 1, 2, 3, and 10 to 12 months. Improvements in tremor and rigidity remained relatively constant, while there was some apparent loss of efficacy in timed tests and quality of timed tests. Amantadine appears effective in the long-term treatment of some patients with Parkinson's disease.

This research was supported by a grant from E. I. Du Pont de Nemours and Company, Inc.

Received for publication December 13, 1974.

Reprint requests should be addressed to Dr. Butzer at Department of Neurology, University of Iowa Hospitals, Iowa City, IA 52242.

This article has been cited by other articles:

				M. P. Hill, P. Ravenscroft, E. Bezard, A. R. Crossman, J. M. Brotchie, A. Michel, R. Grimee, and H. Klitgaard Levetiracetam Potentiates the Antidyskinetic Action of Amantadine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-Lesioned Primate Model of Parkinson's Disease J. Pharmacol. Exp. Ther., July 1, 2004; 310(1): 386 - 394. [Abstract] [Full Text] [PDF]

				A. Colcher and M. B. Stern Therapeutics in the Neurorehabilitation of Parkinson's Disease Neurorehabil Neural Repair, December 1, 1999; 13(4): 205 - 218. [Abstract] [PDF]

				G. W. Paulson Therapy of Patients With Parkinson's Disease Arch Neurol, August 1, 1994; 51(8): 754 - 756. [Abstract] [PDF]

				W. C. Koller Pharmacologic Treatment of Parkinsonian Tremor Arch Neurol, February 1, 1986; 43(2): 126 - 127. [Abstract] [PDF]